Pharmacological modulation of reactive oxygen species in cancer treatment

Area of Science:

• Biochemistry
• Cell Biology
• Oncology

Background:

• Mammalian aerobic metabolism generates reactive oxygen species (ROS), necessitating cellular antioxidant systems like glutathione.
• Cancer cells develop mechanisms to evade oncogenic stress and cell death, complicating traditional therapies.
• Proteotoxic stress, the accumulation of damaged proteins, is elevated in tumor cells.

Purpose of the Study:

• To investigate the anticancer potential of 2-phenylethinesulfoxamine (PES).
• To explore PES's mechanism of action, focusing on proteotoxicity and oxidative stress.
• To assess the synergistic effects of PES with glutathione depletion in cancer treatment.

Main Methods:

• Treatment of cancer cells with PES to assess its impact on proteotoxicity and oxidative stress.
• Evaluation of p53 activation in response to PES treatment.
• Combination therapy using PES and L-buthionine-sulfoximine (BSO) to deplete glutathione.

Main Results:

• PES was found to disable cellular protective mechanisms against proteotoxicity.
• PES treatment induced significant oxidative stress and activated the p53 pathway.
• The combination of PES and BSO demonstrated synergistic anticancer effects.
• Reactive oxygen species (ROS) were identified as central players in feedback loops involving p53, proteotoxicity, autophagy, and mitochondrial dynamics.

Conclusions:

• PES exhibits anticancer selectivity by targeting increased proteotoxic stress in tumor cells.
• PES induces oxidative stress and activates p53, contributing to its therapeutic effect.
• The interplay between ROS, p53, proteotoxicity, and other cellular processes presents a network of targets for novel cancer drug discovery.